These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Cras A; Darsin-Bettinger D; Balitrand N; Cassinat B; Soulié A; Toubert ME; Delva L; Chomienne C Oncogene; 2007 Jun; 26(27):4018-24. PubMed ID: 17213810 [TBL] [Abstract][Full Text] [Related]
25. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934 [TBL] [Abstract][Full Text] [Related]
26. Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells. Whang YM; Choi EJ; Seo JH; Kim JS; Yoo YD; Kim YH Cancer Chemother Pharmacol; 2005 Nov; 56(5):543-55. PubMed ID: 15959780 [TBL] [Abstract][Full Text] [Related]
27. Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity. Klan N; Seuter S; Schnur N; Jung M; Steinhilber D Biol Chem; 2003 May; 384(5):777-85. PubMed ID: 12817474 [TBL] [Abstract][Full Text] [Related]
28. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345 [TBL] [Abstract][Full Text] [Related]
29. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013 [TBL] [Abstract][Full Text] [Related]
30. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Pan XQ; Zheng X; Shi G; Wang H; Ratnam M; Lee RJ Blood; 2002 Jul; 100(2):594-602. PubMed ID: 12091353 [TBL] [Abstract][Full Text] [Related]
31. Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-beta1 induced murine tissue inhibitor of metalloproteinases-1 gene expression. Young DA; Billingham O; Sampieri CL; Edwards DR; Clark IM FEBS J; 2005 Apr; 272(8):1912-26. PubMed ID: 15819885 [TBL] [Abstract][Full Text] [Related]
32. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells. Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739 [TBL] [Abstract][Full Text] [Related]
33. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus. Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998 [TBL] [Abstract][Full Text] [Related]
34. Differential effects of histone deacetylase inhibitors on interleukin-18 gene expression in myeloid cells. Koyama N; Koschmieder S; Tyagi S; Nürnberger H; Wagner S; Böcker U; Hoelzer D; Gerhard Ottmann O; Kalina U Biochem Biophys Res Commun; 2002 Apr; 292(4):937-43. PubMed ID: 11944905 [TBL] [Abstract][Full Text] [Related]
35. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Raffoux E; Chaibi P; Dombret H; Degos L Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941 [TBL] [Abstract][Full Text] [Related]
36. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. Cho HH; Park HT; Kim YJ; Bae YC; Suh KT; Jung JS J Cell Biochem; 2005 Oct; 96(3):533-42. PubMed ID: 16088945 [TBL] [Abstract][Full Text] [Related]
37. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Coffey DC; Kutko MC; Glick RD; Butler LM; Heller G; Rifkind RA; Marks PA; Richon VM; La Quaglia MP Cancer Res; 2001 May; 61(9):3591-4. PubMed ID: 11325825 [TBL] [Abstract][Full Text] [Related]
38. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
39. Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Wang H; Zheng X; Behm FG; Ratnam M Blood; 2000 Nov; 96(10):3529-36. PubMed ID: 11071651 [TBL] [Abstract][Full Text] [Related]
40. MMP28 gene expression is regulated by Sp1 transcription factor acetylation. Swingler TE; Kevorkian L; Culley KL; Illman SA; Young DA; Parker AE; Lohi J; Clark IM Biochem J; 2010 Apr; 427(3):391-400. PubMed ID: 20144149 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]